Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Okabe, Seiichi ^a   Tauchi, Tetsuzo ^a   Tanaka, Yuko ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; NILOTINIB; PROTEIN KINASE LYN; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; LYN PROTEIN-TYROSINE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; LEUKEMIA CELL LINE; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; HUMAN; LETTER; PATHOLOGY;

APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES;

EID: 79960873884     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-32     Document Type: Article

References (9)

1. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Deininger M, Buchdunger E, Druker BJ, Blood 2005 105 2640 2653 10.1182/blood-2004-08-3097 15618470 (Pubitemid 40446252)
2. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J, Ann Intern Med 2006 145 913 923 17179059 (Pubitemid 351639967)
3. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG, N Engl J Med 2006 354 2542 2551 10.1056/NEJMoa055104 16775235 (Pubitemid 43882350)
4. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, ENESTnd Investigators, N Engl J Med 2010 362 2251 2259 10.1056/NEJMoa0912614 20525993
5. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. Wei G, Rafiyath S, Liu D, J Hematol Oncol 2010 3 47 10.1186/1756-8722-3-47 21108851
6. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, O'Brien S, Giles F, Talpaz M, Cortes J, Blood 2007 109 497 499 10.1182/blood-2006-07-035493 16990591 (Pubitemid 46105944)
7. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M, N Engl J Med 2010 362 2260 2270 10.1056/NEJMoa1002315 20525995
8. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG, J Hematol Oncol 2011 4 6 10.1186/1756-8722-4-6 21299849
9. Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells. O'Laughlin-Bunner B, Radosevic N, Taylor ML, DeBerry C, Metcalfe DD, Zhou M, Lowell C, Linnekin D, Blood 2001 98 343 350 10.1182/blood.V98.2.343 11435302